Beta-acid-loaded pH-responsive magnetic Fe3O4 modified chitosan nano-particles as well as preparation method and application of beta-acid-loaded pH-responsive magnetic Fe3O4 modified chitosan nano-particles

By preparing β-acid-loaded pH-responsive magnetic Fe3O4 modified chitosan nanoparticles, the problem of lack of pH and magnetic stimulation response in the prior art is solved, and the dual function of colorectal cancer treatment and intestinal microbiota regulation is achieved. and demonstrate good biosafety and therapeutic effects.

CN118948802AInactive Publication Date: 2024-11-15NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411044697.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The nanoparticles prepared in the prior art do not have the characteristics of pH and magnetic stimulation response, and are difficult to achieve accurate drug release, and cannot both treat colorectal cancer and regulate intestinal bacterial flora.

Method used

Chitosan, sodium tripolyphosphate and iron tetraoxide were used to prepare β-acid-loaded magnetic Fe3O4 modified chitosan nanoparticles, and the mixture of acetic acid solution and ethanol solution, the addition of Fe3O4 and the intersection of sodium tripolyphosphate. The nanoparticles are formed that can release drugs under pH changes and magnetic fields.

Benefits of technology

The targeted release of nanoparticles under pH and magnetic field conditions was achieved, which significantly inhibited the growth of colorectal cancer cells, regulated the intestinal flora, and had good biosafety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948802A_ABST
    Figure CN118948802A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine and tumor treatment, and particularly relates to beta-acid-loaded pH response magnetic Fe3O4 modified chitosan nanoparticles and a preparation method and application thereof.The preparation method comprises the following steps that chitosan is added into an acetic acid solution and stirred to be dissolved, and a chitosan aqueous solution is prepared; mixing and stirring a beta-acid ethanol solution and a chitosan aqueous solution to obtain a mixed solution I; adding Fe3O4 into the mixed solution I, and stirring to obtain a mixed solution II; and mixing and stirring a sodium tripolyphosphate solution and the mixed solution 2, and centrifuging to obtain the beta-acid-loaded pH response magnetic Fe3O4 modified chitosan nanoparticles. The nanoparticles prepared in the invention can be successfully ingested by HCT116 cells, a mouse in-vivo safety experiment finds that the drug-loaded nanoparticles are safe, and a mouse in-situ colorectal cancer animal model experiment shows that the drug-loaded nanoparticles can significantly inhibit the development of colorectal cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and tumor treatment, and specifically relates to a pH-responsive magnetic Fe3O4-modified chitosan nanoparticle loaded with beta-acid, and a preparation method and application thereof. Background Art

[0002] Nowadays, colorectal cancer (CRC) is a common gastrointestinal malignancy, and patients account for 9.4% of the global death toll each year. At present, the treatment of colorectal cancer mainly relies on surgery and chemotherapy, but some patients still die from cancer recurrence and metastasis. During tumor treatment, the intestinal flora is in a dynamic equilibrium state. Colorectal cancer chemotherapy drugs (5-fluorouracil, mitomycin, doxorubicin, etc.) have large toxic side effects, poor in vivo selectivity, lack of targeting, and are mostly administered by intravenous infusion, and oral administration (for example, uracil tegafur tablets, capecitabine tablets) is less. Although oral administration can significantly improve patient acceptance and compliance compared with other modes of administration, oral administration still faces many challenges such as poor drug solubility, complex gastrointestinal environment, and nonspecific distribution of drugs in the gastrointestinal tract. In order to effectively overcome the shortcomings of oral administration, nanotechnology is used to prepare nanoparticles carrying active ingredients for administration, which can enhance the ability of drugs to penetrate the intestinal barrier, reduce systemic adverse reactions, and improve the potential for treatment efficiency. Oral medication is also the most convenient way to regulate intestinal microorganisms. Therefore, developing a new drug delivery system to release anti-tumor drugs from the colon, improve the tumor targeting of anti-tumor drugs, and reduce the dosage is of great significance for the clinical treatment of colorectal cancer.

[0003] Chemotherapy drugs have been used for a long time, and patients have developed drug resistance, but the development cycle of new drugs is long and the R&D cost is high. Natural products have always attracted the attention of researchers, and the application of active anti-tumor substances in natural plants is a frontier field of anti-tumor research. Hops are perennial plants widely planted in the world. Hops resin is an important secondary metabolite, from which α-acid, β-acid, α-stearic acid, β-stearic acid, polyphenols and volatile oils can be isolated. β-acid can be obtained from hop extracts. It is reported that β-acid has a significant inhibitory effect on colorectal cancer cells (Caco-2, SW620, HT29, HCT116), prostate cancer cells (PC3, DU145), and breast cancer cells (MCF-7, MDA-MB-231). In addition, β-acid also has the characteristics of inhibiting the growth of different types of bacteria. β-acid has dual anti-cancer and antibacterial effects, and can play a positive role in the clinical treatment of colorectal cancer.

[0004] Natural and / or synthetic biomaterials have been widely used in the preparation of nano drug carriers. Natural polymers have the advantages of low toxicity, good biocompatibility, biodegradability and easy access. Among different types of natural biomaterials, chitosan has attracted much attention due to its wide application, high biocompatibility, high mechanical strength and biodegradability. Chitosan is the second largest polysaccharide in the world in terms of annual production after cellulose. It is composed of N-acetyl-D-glucosamine and β-(1-4)-d-glucosamine. Chitosan can be dissolved under acidic conditions to produce a protonation reaction, which makes chitosan a cationic polymer that can interact with different types of molecules. The presence of hydroxyl and amino groups in its structure allows chitosan to react with other groups. Nanoparticles with chitosan as the main substrate have been widely used in drug delivery. Studies have found that different materials constituting nanoparticles affect their physical and chemical properties. The researchers loaded natural products (curcumin, resveratrol, quercetin, camptothecin, etc.) into chitosan-based nanoparticles. In vitro studies have found that the nanoparticles have a significant inhibitory effect on cancer cells, and the anticancer activity of drug-loaded nanoparticles is superior to that of free drugs. The researchers used sodium tripolyphosphate as a cross-linking agent to prepare chitosan nanoparticles loaded with β-acid and found that the drug-loaded nanoparticles had a good inhibitory effect on colorectal cancer cells (HCT116 and HT29), but had no significant cytotoxicity to normal human intestinal epithelial cells (NCM460).

[0005] Almeida et al. successfully loaded camptothecin into chitosan micelles modified with polyethylene glycol and oleic acid. The results of subsequent in vivo anticancer studies reported that oral administration of drug-loaded micelles significantly reduced tumor incidence and inflammatory signs. In the study of nanoparticle delivery of paclitaxel to treat colorectal cancer mice, it was confirmed that drug-loaded nanoparticles not only had a good therapeutic effect on colorectal cancer, but also could change the number and structure of bacteria in the intestinal flora. The above results verified that nanoparticles loaded with active ingredients can not only effectively treat colorectal cancer, but also play a colorectal cancer inhibitory effect by regulating intestinal flora. Since chitosan has good biocompatibility among many natural biomaterials, more studies have loaded active small molecules into chitosan nanoparticles, changing the drug release effect from the original sudden release to slow release, prolonging the drug's action time, improving bioavailability, and helping to reduce the number of dosing times for patients. Generally speaking, the pH value of the stomach is close to 1.2, the pH value of the small intestine is about 6.0-6.8, the pH value of the end of the small intestine is 6.8-7.0, and the pH value of the colon is 6.5-7.5. Previous in vitro drug release studies have found that the release of β-acid from nanoparticles depends on changes in pH. The rise of the concept of targeted drug delivery has led to the development of nanoparticle drug delivery research. After the nanoparticles are modified with magnetic molecules, the drug can be targeted and enriched in the colorectal area under an external magnetic field, ultimately inhibiting the development of tumors.

[0006] However, the nanoparticles prepared in the prior art do not have the characteristics of pH and magnetic stimulation response, so it is difficult to achieve accurate drug release in drug release research; and the above nanoparticles cannot both treat colorectal cancer and regulate intestinal flora. Therefore, it is urgent to provide a product that can overcome the above defects for the treatment of colorectal cancer. Summary of the invention

[0007] The purpose of the present invention is to provide a pH-responsive magnetic Fe3O4-modified chitosan nanoparticle loaded with β-acid, and a preparation method and application thereof. The β-acid-loaded nanoparticles are prepared by using chitosan, sodium tripolyphosphate and ferrosoferric oxide, which can not only treat colorectal cancer, but also regulate intestinal flora and have good biosafety.

[0008] The objective of the present invention is achieved through the following technical solutions:

[0009] The present invention provides a method for preparing pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid, comprising the following steps:

[0010] (1) adding chitosan to an acetic acid solution, stirring and dissolving, and preparing a chitosan aqueous solution;

[0011] (2) mixing the β-acid ethanol solution with the chitosan aqueous solution prepared in step (1) to obtain a mixed solution 1;

[0012] (3) adding Fe3O4 to the mixed solution 1 prepared in step (2), and stirring to obtain a mixed solution 2;

[0013] (4) Mixing the sodium tripolyphosphate solution with the mixed solution 2 prepared in step (3), and centrifuging to obtain the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid.

[0014] Furthermore, in step (1), the concentration of the acetic acid solution is 1-2%, and the concentration of chitosan in the chitosan aqueous solution is 1-20 mg / mL.

[0015] Furthermore, in step (2), the β-acid ethanol solution is a solution with a concentration of 1-50 mg / mL prepared by dissolving β-acid in anhydrous ethanol, the mixing ratio of the β-acid ethanol solution to the chitosan aqueous solution is 1:1-1:5, and the stirring is stirring at room temperature for 10-90 min.

[0016] Furthermore, in step (3), the amount of Fe3O4 added is 200-600 mg, and the stirring is carried out at room temperature for 1-2 hours.

[0017] Furthermore, in step (4), the concentration of the sodium tripolyphosphate solution is 1-10 mg / mL, the mass ratio of the mixed solution 2 to the sodium tripolyphosphate solution is 2:1, and the stirring is carried out at room temperature for 1-2 hours.

[0018] The invention also provides pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with beta-acid prepared by the preparation method.

[0019] The present invention also provides the use of the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid in the preparation of antibacterial drugs, wherein the antibacterial drugs include inhibiting Escherichia coli and Staphylococcus aureus.

[0020] The present invention also provides the use of the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with beta-acid in the preparation of anticancer drugs.

[0021] Furthermore, the anti-cancer effect is anti-colorectal cancer.

[0022] Furthermore, the colorectal cancer is colorectal cancer cell HCT-116.

[0023] The beneficial effects of the present invention are:

[0024] β-acid is an effective ingredient from the natural plant hops. Previous studies have found that β-acid has a good inhibitory effect on different types of bacteria and cancer cells. In order to expand the application range of β-acid, the present invention designs the use of chitosan, sodium tripolyphosphate, and ferric oxide to prepare nanoparticles loaded with β-acid. The present invention verifies the nanoparticles using characterization techniques such as infrared, scanning electron microscopy, and transmission electron microscopy. In the property study, it was found that the nanoparticles loaded with β-acid can maintain the antibacterial and anticancer properties of pure β-acid. In addition, the chitosan magnetic nanoparticles loaded with β-acid can be successfully taken up by HCT116 cells. The in vivo safety experiment in mice found that the drug-loaded nanoparticles are safe, and the in situ colorectal cancer animal model experiment in mice showed that the drug-loaded nanoparticles can significantly inhibit the development of colorectal cancer. At the same time, the nanoparticles can not only treat colorectal cancer, but also regulate intestinal flora, and have good biosafety. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0026] Figure 1The electron microscope scanning, infrared spectrum, X-ray diffraction, particle size and potential diagram of the nanoparticles prepared in the examples of the present invention. A is an infrared spectrum diagram, in A (a) is the FTIR spectrum of CS, (b) is the FTIR spectrum of β-acid, (c) is the FTIR spectrum of Fe3O4, (d) is the FTIR spectrum of TPP, (e) is the FTIR spectrum of Fe3O4 / CS / TPP, and (f) is the FTIR spectrum of 9Fe3O4 / CS / TPP / β-acid; B is the XRD spectrum of CS, β-acid, TPP, Fe3O4, Fe3O4 / CS / TPP and 9Fe3O4 / CS / TPP / β-acid, in B (a) is the XRD spectrum of CS, (b) is the XRD spectrum of β-acid, (c) is the XRD spectrum of TPP, (d) is the FTIR spectrum of TPP, (e) is the FTIR spectrum of Fe3O4 / CS / TPP, and (f) is the FTIR spectrum of 9Fe3O4 / CS / TPP / β-acid. c) is the XRD spectrum of TPP, (d) is the XRD spectrum of Fe3O4, (e) is the XRD spectrum of Fe3O4 / CS / TPP, and (f) is the XRD spectrum of 9Fe3O4 / CS / TPP / β-acid; C is a typical SEM image of blank nanoparticles (Fe3O4 / CS / TPP) and drug-loaded nanoparticles (9Fe3O4 / CS / TPP / β-acid), among which (a1) is the 1μm SEM image of Fe3O4 / CS / TPP, (a2) is the 500nm SEM image of Fe3O4 / CS / TPP, and (b1) is the 3Fe3O4 / CS / (b2) is the 1 μm SEM image of TPP / β-acid, (c1) is the 1 μm SEM image of 6Fe3O4 / CS / TPP / β-acid, (c2) is the 500 nm SEM image of 6Fe3O4 / CS / TPP / β-acid; (d1) is the 1 μm SEM image of 9Fe3O4 / CS / TPP / β-acid, (d2) is the 500 nm SEM image of 9Fe3O4 / CS / TPP / β-acid; D is the SEM image of Fe3O4 / CS / TPP and Fe3O4 / CS / TPP at 300 K. Hysteresis loop of O4 / CS / TPP / β-acid; E is the external magnetic field effect of 9Fe3O4 / CS / TPP / β-acid (a1 and a2) without water and (b1 and b2) with water; F is the TEM image of Fe3O4 / CS / TPP (a1) 100nm, (a2) 50nm; 3Fe3O4 / CS / TPP / β-acid (b1) 100nm, (b2) 50nm; 6Fe3O4 / CS / TPP / β-acid (c1) 100nm, (c2) 50nm; 9Fe3O4 / CS / TPP / β-acid (d1) 100nm, (d2) 50nm;

[0027] Figure 2is the in vitro release profile of β-acid in nanoparticles, wherein A is 3Fe3O4 / CS / TPP / β-acid, B is 6Fe3O4 / CS / TPP / β-acid, and C is 9Fe3O4 / CS / TPP / β-acid;

[0028] Figure 3 The graph is a graph of the bacterial inhibition activity of the drug-loaded nanoparticles prepared by the present invention against common clinical strains, wherein A is the total bacterial colony count (a1) and molecular docking (a2) of the β-acid-loaded nanoparticles against Escherichia coli, B is the total bacterial colony count (b1) and molecular docking (b2) of the β-acid-loaded nanoparticles against Staphylococcus aureus, and C is the total bacterial colony count (c1) and molecular docking (c2) of the β-acid-loaded nanoparticles against Acinetobacter baumannii;

[0029] Figure 4 Figure 1 is a graph showing the inhibitory effect of the drug-loaded nanoparticles prepared by the present invention on colorectal cancer cells, wherein the cell viability graphs of β-acid, 5-FU, Fe3O4 / CS / TPP, 3Fe3O4 / CS / TPP / β-acid, 6Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid on colorectal cancer cells are shown in Figures AD, A and B are HCT116, C and D are NCM460; E is a cell migration experiment of control, 5-FU and 9Fe3O4 / CS / TPP / β-acid on HCT116; F is a fluorescence image and quantitative Analysis, cell nuclei and apoptosis were stained with Hoechst33342 (blue) and caspase-3 marker (green), respectively, and the measurement indicators were: cell number, average DNA concentration, average nuclear area, nuclear fragmentation index, percentage of apoptotic cells, and average intensity of caspase-3 / 7; G is a representative CLSM image of HCT116 cells after incubation with Fe3O4 / CS / TPP / coumarin 6 and Fe3O4 / CS / TPP / β-acid + coumarin 6 for 2 hours, cell nuclei were stained with DAPI (blue), and Fe3O4 / CS / TPP was stained with coumarin 6 (green);

[0030] Figure 5 Figure 1 is a safety validation diagram of nanoparticles, including (A) the effects of PBS, 5-FU, β-acid, Fe3O4 / CS / TPP, 9Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid+5-FU on the body weight of healthy C57 / BL6 mice (n=3); (B-D) serum biochemical analysis of mice treated with different methods (n=3): (B) red blood cells; (C) lymphocytes; (D) white blood cells; (E) H&E staining (100nm) evaluation of major organs;

[0031] Figure 6Figure 2 shows the in vivo antitumor activity of 9Fe3O4 / CS / TPP / β-acid, including (A) experimental time of drug treatment group, (B) tumor weight of different groups, (C) weight change of different groups, (D) change of fluorescence intensity in mice before and after treatment, (E) representative gastrointestinal specimens of designated treatment groups, (F) H&E stained sections of colorectal and tumor tissues; blue asterisks indicate tumor areas, green arrows indicate tumor-invasive colon mucosa, and the scale bar is 200 μm. DETAILED DESCRIPTION

[0032] The embodiments of the present invention are described in detail below, and the embodiments are intended to explain the present invention and should not be construed as limiting the present invention. If specific techniques or conditions are not specified in the embodiments, they are carried out according to the techniques or conditions described in the literature in this area or according to the product specifications. If the manufacturers of reagents or instruments are not specified, they are all conventional products that can be obtained commercially.

[0033] In order to have a clearer understanding of the technical features, purposes and effects of the present invention, the specific implementation methods of the present invention are now described.

[0034] The specific preparation method of the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid provided by the present invention is:

[0035] (1) adding chitosan to an acetic acid solution with a concentration of 1-2%, stirring and dissolving at room temperature (25° C.) to prepare a chitosan aqueous solution with a concentration of 1-20 mg / mL; the concentration of the acetic acid solution is preferably 1%;

[0036] (2) adding a β-acid ethanol solution having a concentration of 1-50 mg / mL to the chitosan aqueous solution obtained in the above step (1) at a ratio of 1:1-1:5, and stirring for 10-90 minutes at room temperature (25° C.) to obtain a mixed solution; the β-acid ethanol solution is prepared by dissolving β-acid in anhydrous ethanol;

[0037] (3) Add 200-600 mg of Fe3O4 to the solution in step 2, and stir for 1-2 h at room temperature (25°C) to obtain a mixed solution;

[0038] (4) preparing a sodium tripolyphosphate solution with a concentration of 1-10 mg / mL, wherein the mass ratio of the mixed solution obtained in step (3) to the sodium tripolyphosphate solution is 2:1, adding sodium tripolyphosphate to the mixed solution obtained in the above step (3), continuing to stir at room temperature (25° C.) for 1-2 hours, stopping stirring, and centrifuging to obtain nanoparticles; the sodium tripolyphosphate solution is prepared by dissolving sodium tripolyphosphate in deionized water; and the volume ratio of the above chitosan solution to the sodium tripolyphosphate solution is selected from 1:0.1-1:1.

[0039] The following examples are used to further illustrate the present invention, but are not intended to limit the present invention.

[0040] Example 1

[0041] The specific preparation method of pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid in Example 1 comprises the following steps:

[0042] 600 mg of chitosan (CS) was added to 200 mL (1% v / v) of acetic acid solution, stirred to dissolve, and undissolved substances were filtered to obtain the final CS solution (3 mg / mL). 1.8 g of β-acid was accurately weighed and dissolved in 40 mL of ethanol to obtain a final solution (45 mg / mL). β-acid / ethanol solution (7 mL) was slowly dripped into the CS solution and stirred for 1 hour to make the mixture uniform. 300 mg of Fe3O4 nanoparticles were placed in 20 mL of water, ultrasonically dispersed uniformly, and added dropwise to the reaction solution for 1 hour. Finally, 2 mg / mL of sodium tripolyphosphate solution was slowly dripped, stirred at 800 rpm and 25°C for 1 hour, and the formed nanoparticles were centrifuged at 12000×g for 10 minutes at 4°C and washed 3 times with deionized water. Nanoparticles were prepared by freeze drying.

[0043] Example 2

[0044] The specific preparation method of pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid in Example 2 is different from that in Example 1, except that the amount of β-acid / ethanol solution added is 15 mL.

[0045] Example 3

[0046] The specific preparation method of pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid in Example 3 is different from that in Example 1, except that the dripping amount of the β-acid / ethanol solution is 22.5 mL.

[0047] Test Example 1

[0048] This test example aims to verify the physical properties of the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid prepared in the above examples, including the following tests on the nanoparticles prepared in the above examples: electron microscopy scanning, infrared spectroscopy, X-ray diffraction, particle size and potential, drug loading and encapsulation efficiency, and release.

[0049] (I) Infrared spectroscopy

[0050] In this experiment, the nanoparticles prepared in the example were characterized by FTIR for the first time. CS( Figure 1 A(a) appears at 3364cm -1Different studies have shown that this is related to the -OH vibration in CS. -1 The absorption peaks observed at 1655cm are the asymmetric and symmetric vibrations of CH. -1 、1597cm -1 and 1381cm -1 The absorption peaks near 1083cm are related to the different vibration modes of the NH bond (amide I, amide II and amide III) in CS. -1 The absorption peak at 3406 cm is related to the CO stretching vibration. In the FTIR characterization, β-acid was found as the active component. -1 There is a strong and broad OH absorption peak at ( Figure 1 A(b)). 2970cm -1 The absorption peak formed near 1665cm is the CH stretching vibration absorption. -1 The absorption peak at 573 cm-1 and 1624 cm-1 are the absorption peaks of C=O in the β-acid structure. -1 The weak peak at is due to the stretching vibration of the Fe-O bond ( Figure 1 A(c)). The FTIR absorption spectrum of the crosslinking agent TPP is located at 1169 cm -1 and 900cm -1 , which are related to the stretching vibrations of PO and POP, respectively ( Figure 1 A(d)). After the nanoparticles are formed by ion gel method, various studies have found that the hydroxyl groups between different molecules can form intermolecular interactions, thus affecting the shift of the absorption peak. This experiment also found this trend of change. Fe3O4 / CS / TPP at 3232cm -1 There is a broad peak at the position of the molecule. This phenomenon may be caused by the hydrogen bonding force between different molecules ( Figure 1 A(e) in CS). The absorption peaks of the amide bond in CS also shifted to 1636 cm -1 、1538cm -1 and 1395cm -1 .Fe3O4 at 1624cm -1 The absorption peak at 1636cm -1 ). Due to the change of amide bond, NH3 + Electrostatic interactions occur between the phosphate groups in TPP and Fe3O4, forming a more complex structure. The addition of β-acid changes the FTIR absorption spectrum. The -OH in β-acid interacts with the blank nanoparticles (Fe3O4 / CS / TPP), causing the absorption peak of -OH to shift to 3363 cm -1 , forming a β-acid-specific absorption peak of 2971 cm-1 Compared with the blank nanoparticles, the -1 、1538cm -1 and 1395cm -1 The absorption peak at 1631 cm -1 、1541cm -1 and 1390cm -1 Department Figure 1 A(f)). The above FTIR experimental results show that the present invention successfully prepared β-acid-loaded stimulus-responsive nanoparticles.

[0051] (II) XRD results

[0052] Figure 1 Where B is the XRD spectra of CS, β-acid, TPP, Fe3O4, Fe3O4 / CS / TPP and 9Fe3O4 / CS / TPP / β-acid. Figure 1As shown in Figure B, CS has a high-intensity CHs diffraction peak at 2θ=20.25°, indicating that the amino and hydroxyl groups in CS form hydrogen bonds and have strong crystallinity. Pure β-acid has characteristic absorption peaks at 2θ=8.31°, 9.40°, 10.20°, 12.71°, 15.62°, 17.60°, 19.84°, 21.13°, 22.67°, 23.79° and 24.83°, indicating that β-acid has a certain degree of crystallinity. The absorption peaks of the crosslinker TPP are 2θ=11.31°, 19.65°, 25.04°, 29.89°, 33.57°, 45.05°, 55.59° and 58.96°. The synthesized pure Fe3O4 was characterized by XRD, and peaks at 2θ=30.44°, 35.79°, 43.21°, 53.29°, 57.01° and 62.99° were found on the XRD standard card (JCPDS card NO.19-629). XRD analysis confirmed that the synthesized Fe3O4 was composed of (220), (311), (400), (422), (511) and (620) crystal planes, supported by the corresponding oriented peaks. The grain size of pure Fe3O4 was estimated using Scherrer's equation and was finally calculated to be about 12.91nm, which may lead to the supermagnetism of the developed system. After CS, TPP and Fe3O4 formed nanoparticles, the diffraction peaks of the nanoparticles shifted and tended to broaden. Other studies have found that this may be due to the formation of intermolecular hydrogen bonds between TPP and CS, resulting in the loss of the original natural crystal structure of chitosan. Another explanation is that the diffraction peak width of the crystalline powder is also closely related to the size of the crystal, while the change in the diffraction peak width is related to the presence of the amorphous phase. After the nanoparticles are formed, the original orderly arrangement of the CS molecules is broken, and the addition of Fe3O4 allows the nanoparticles to maintain supermagnetic properties. When the nanoparticles are loaded with β-acid, the diffraction peak becomes wider, which may be due to the amorphous structure formed by the introduction of β-acid.

[0053] (III) Scanning electron microscope

[0054] Typical SEM images of blank nanoparticles (Fe3O4 / CS / TPP) and drug-loaded nanoparticles (9Fe3O4 / CS / TPP / β-acid) are shown in Figure 2. Figure 1 As shown in C. Figure 1As can be seen in C (a), the Fe3O4 nanoparticles combined with CS and TPP have a good spherical structure and a rough surface. As the amount of β-acid loading increases, the particle size of the nanoparticles also tends to increase. The scanning electron microscope image can serve as strong evidence for the successful preparation of β-acid nanoparticles with dual stimulus response. At the same time, since the composite nanoparticles themselves have a small particle size, high surface energy and surface activity, they are very easy to attract each other and form stable agglomerates. However, the scanning electron microscope results are only carried out under dry conditions and cannot accurately reflect the specific state in the liquid.

[0055] (IV) Magnetic performance test

[0056] To demonstrate the magnetic properties of the nanoparticles, the applicant collected the magnetization hysteresis lines of unloaded and drug-loaded Fe3O4 magnetic nanoparticles at 300K ( Figure 1 D). The experiment found that the saturation magnetization intensity (σs) of blank magnetic nanoparticles is about 11.87emu / g, while the saturation magnetization intensity of drug-loaded magnetic nanoparticles is about 7.19emu / g. Figure 1 As can be seen from D, the σs after coating is reduced. The reduction in magnetization intensity is mainly due to the polymer coating on the surface of the magnetic nanoparticles. Similarly, in the applicant's experiment, the obtained magnetic nanoparticles were fixed on the wall of the test tube for 60s ( Figure 1 (E). Macroscopic experiments also verified that the magnetic nanoparticles formed after different modifications of CS, TPP and β-acid also had sufficient saturation magnetization, indicating that the nanoparticles were easy to disperse for solid-liquid separation ( Figure 2 (B) The reduced saturation magnetization of Fe3O4 / CS / TPP and 9Fe3O4 / CS / TPP / β-acid compared to Fe3O4 may be due to the possible formation of a magnetic dead layer by CS, TPP, and β-acid. Any crystal disorder within the surface layer may also lead to a significant reduction in the saturation magnetization of the nanoparticles due to the significant proportion of surface atoms. In addition, Figure 1 As can be seen in Figure D, at low magnetic fields, the hysteresis loop does not remain, so the coercivity is almost negligible in the absence of an external magnetic field. This indicates that Fe3O4 / CS / TPP and 9Fe3O4 / CS / TPP / β-acid have superparamagnetism at room temperature, which is crucial for pharmaceutical and biomedical applications.

[0057] (V) Transmission electron microscopy, charge and particle size analysis

[0058] Using transmission electron microscopy ( Figure 1F) The morphology of Fe3O4 (ferroferric oxide nanoparticles), Fe3O4 / CS / TPP (ferroferric oxide nanoparticles cross-linked with chitosan), 3Fe3O4 / CS / TPP / β-acid, 6Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid (the latter three nanoparticles represent ferroferric oxide nanoparticles cross-linked with chitosan with different drug loadings in Examples 1-3) nanoparticles was characterized. The magnetic Fe3O4 prepared in the experiment was almost ellipsoidal. The average particle size of the Fe3O4 / CS / TPP nanoparticles was 233nm and the standard deviation was 3.74nm. The particle sizes of the prepared drug-loaded nanoparticles were 238, 270 and 381nm, respectively, which further confirmed that the addition of β-acid had a significant effect on the particle size of the drug-loaded nanoparticles. Studies have shown that it is difficult to observe the interaction between Fe3O4 and CS under TEM. Compared with the nanoparticles without β-acid, the dispersion behavior of the drug-loaded nanoparticles was statistically different and showed an aggregated morphology. The introduction of β-acid also affected the zeta potential of the nanoparticles (as shown in Table 1). The zeta potential of Fe3O4 / CS / TPP nanoparticles was +2.16 mV. Analysis suggests that this may be due to the amino groups (NH3 + ) is positively charged under acidic conditions, and there is an obvious repulsion between positive charges, which makes the nanoparticles also have positive charge behavior. With the addition of β-acid, the zeta potential range and amplitude of the nanoparticles are significantly increased compared with the blank. The increase in zeta potential value is related to the expansion of particle size distribution due to the addition of β-acid. Compared with blank nanoparticles, the size of drug-carrying nanoparticles fluctuates. It is reported that bacteria carry a large amount of negative charge, so the nanoparticles prepared by the present invention can interact with bacteria and cause bacterial death. Studies have shown that the high positive charge of nanomaterials can enhance the interaction with bacteria through electrostatic attraction.

[0059] (VI) Drug loading and encapsulation efficiency

[0060] The encapsulation efficiency (EE) and drug loading (LC) of β-acid in nanoparticles were determined by UV spectroscopy. According to UV analysis, the drug loading (LC) ranged from 4.55% to 37.48%, and the encapsulation efficiency (LC) ranged from 30.91% to 83.56% (as shown in Table 1).

[0061] Table 1 Size, polydispersity index (PDI), zeta potential, drug loading (LC) and encapsulation efficiency (EE) of Fe3O4 / CS / TPP nanoparticles loaded with β-acid

[0062]

[0063] (VII) Release

[0064] The particles were incubated in different pH buffer solutions (pH = 7.4, 6.6 and 1.2, simulating normal human tissue, tumor microenvironment and gastric fluid environment, respectively) at 37°C. The experiment found that under the three different pH conditions, there was a rapid release (burst release) followed by a slow release (specifically Figure 2 shown).

[0065] Test Example 2

[0066] This test example aims to verify the antibacterial, anticancer effects and safety of the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid prepared in the above examples, as follows:

[0067] (I) Inhibitory effect on Staphylococcus aureus and Gram-negative bacteria

[0068] The specific verification steps include: taking Escherichia coli (ATCC25922) strains, adding nutrient broth under sterile conditions, expanding the culture, and culturing at 37°C for 24 hours. Selecting typical colonies and dissolving them in 0.9% (w / v) physiological saline, making the reading of the bacterial turbidity meter 0.50 McFarland turbidity units, and the concentration of 1×10 8 CFU / mL. β-acid and drug-loaded nanoparticles were dispersed in ethanol to obtain solutions of different concentrations (8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 mg / mL). Take 50 μL of bacterial solution (concentration of 1×10 7 CFU / mL) and 100 μL of different concentrations (8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 mg / mL) of the drug solution were incubated at 37°C for 24 h. 100 μL of the bacterial solution cultured the next day was spread on LB solid medium and incubated for 24 h. The bacterial growth was observed and recorded.

[0069] The bacterial counting method was used to determine the bacterial inhibitory activity of β-acid and drug-loaded nanoparticles against common clinical strains (Escherichia coli, Staphylococcus aureus, and Acinetobacter baumannii) (the specific results are shown in Figure 3 As shown). The results show that β-acid and drug-loaded nanoparticles have better antibacterial effects on Staphylococcus aureus than the other two bacteria. The results show that drug-loaded nanoparticles with a concentration greater than 0.125 mg / mL can effectively inhibit Staphylococcus aureus. For Gram-negative bacteria, drug-loaded nanoparticles with a concentration greater than 1 mg / mL can exert an antibacterial effect. This test example selects β-acid as the research object to analyze its binding ability to three bacterial surface membrane proteins. Figure 3(A) shows the interaction between β-acid and Escherichia coli surface membrane proteins. It was found that β-acid interacted with SER-42, ARG-421, SER-732, ARG-583, LEU-124, ALA-123, PHE-127, and GLU-149 through hydrogen bonds, with a binding energy of up to 6.7 Kcal / mol. Figure 3 (B) shows the interaction between β-acid and staphylococcal surface membrane proteins. It was found that β-acid interacted with GLU-149, TYR-182, GLU-50, ASN-156, GLU-159, PHE-166, ASP-47, and ASN-168 through hydrogen bonding, with a binding energy of up to 7.0 Kcal / mol. Figure 3 (C) shows the interaction between β-acid and surface membrane proteins of Acinetobacter baumannii. It was found that there were hydrogen bond interactions between β-acid and GLY-168, ARG-157, ARG-75, ARG-125, ARG-123, ARG-19, ALA-219, SER-217 and PHE-218, with a binding energy as high as 6.9 Kcal / mol.

[0070] (II) Inhibitory effect on colorectal cancer cells

[0071] The specific verification steps include: taking colorectal cancer cells HCT-116 and human normal intestinal epithelial cells NCM460, and inoculating the cells in 96-well plates (1×10 4 Cell density). Let the cells grow for 6 hours to allow for cell attachment. Replace the medium in the 96-well plate with drug-containing medium (McCoy's 5A for HCT-116 cells; DMEM for NCM460 cells) (80, 40, 20, 10, 5 μg / mL) and incubate for 24 hours. Aspirate the drug-containing medium the next day, replace with fresh medium, add 10 μL CCK-8 solution to each well, incubate at 37°C for 1 hour, and measure the optical density (OD) of each well at 450 nm using enzyme labeling.

[0072] The CCK-8 method was used to evaluate the in vitro cytotoxicity of pure β-acid, 5-FU (5-fluorouracil), Fe3O4 / CS / TPP, 3Fe3O4 / CS / TPP / β-acid, 6Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid nanoparticles on HCT116 and NCM460 cell lines. Figure 4A and B show the effects of six materials on the activity of HCT116 cells. As the drug concentration increases, the activity of HCT116 cells decreases. When the concentration of β-acid was in the range of 5-80μg / mL, the survival rate of HCT116 cells varied between 87% and 19%; when the concentration of 5-FU was in the range of 5-80μg / mL, the effect on the survival rate of HCT116 cells was between 43% and 31%; when the concentration of Fe3O4 / CS / TPP was in the range of 5-80μg / mL, the survival rate of HCT116 cells was between 87% and 57%; when the concentration of 3Fe3O4 / CS / TPP / β-acid was in the range of 5-80μg / mL, the cell viability of HCT116 varied between 70% and 47%; when the concentration of 6Fe3O4 / CS / TPP / β-acid was in the range of 5-80μg / mL, the cell survival rate of HCT116 varied between 72% and 24%; when the concentration of 9Fe3O4 / CS / TPP / β-acid was in the range of 5-80μg / mL, the cell survival rate of HCT116 varied between 78% and 24%. IC values ​​of β-acid, 5-FU, Fe3O4 / CS / TPP, 3Fe3O4 / CS / TPP / β-acid, 6Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid on HCT-116 50 The values ​​were 13.25, 1.29, 120.20, 1101.70, 33.95 and 338.81 μg / mL, respectively, which are the IC values ​​of drug-loaded nanoparticles for HCT-116. 50 The range is 33.95-101.7μg / mL.

[0073] For NCM460 cell line, blank nanoparticles promoted the growth of NCM460 in the range of 5-40 μg / mL ( Figure 4 C, D). Similarly, high concentrations of β-acid (40, 80 μg / mL) had a significant inhibitory effect on NCM460 (cell viability was less than 50%). IC values ​​of β-acid, Fe3O4 / CS / TPP, 3Fe3O4 / CS / TPP / β-acid, 6Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid on NCM460 50 They were 32.09, 99.18, 128.10, 77.01 and 87.06 μg / mL respectively.

[0074] In addition, the present invention uses the scratch method to study the different treatments (experimental concentration is IC 50 ) on the migration of HCT116 cells, and found that drug-loaded nanoparticles can effectively inhibit the proliferation of HCT116 cells ( Figure 4E). After 5-fluorouracil and drug-loaded nanoparticles acted on HCT116 cells, the cell migration rates were found to be 31.71% and 11.62%, respectively. This finding well supports the results of the CCK-8 experiment. In summary, the toxic effect of β-acid-loaded magnetic nanoparticles on colorectal cancer cells has been effectively demonstrated in HCT116 cells.

[0075] The applicant also used a cell high-content imaging system to study the inhibitory effects of different drugs on HCT116 cells after 24 hours of incubation. Consistent with the CCK-8 and scratch tests, 9Fe3O4 / CS / TPP nanoparticles showed better inhibitory effects than other groups ( Figure 4 In order to evaluate the targeting of Fe3O4 / CS / TPP nanoparticles, the applicant incubated HCT116 tumor cells with Fe3O4 / CS / TPP labeled with coumarin 6 for 5 hours and observed the tumor cells with a confocal laser scanning microscope at different time points. Figure 4 As shown in G, as the interaction time increases, the fluorescence intensity in the cytoplasm increases, indicating that Fe3O4 / CS / TPP and drug-loaded nanoparticles have time-dependent uptake. The reason for the increase in green fluorescence is analyzed, and its reasonable mechanism may be lectin receptor-mediated cell internalization and positive charge aggregation caused by nanoparticles.

[0076] (III) In vivo anticancer therapeutic effect and safety

[0077] The applicant evaluated the safety of drug-loaded nanoparticles in mice. The mice were treated according to different groups (Control, 5-FU, β-acid, Fe3O4 / CS / TPP, 9Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid+5-FU). The applicant collected blood samples and body weight at different time points and found that the body weight at different time points (such as Figure 5 As shown in A), red blood cell level ( Figure 5 As shown in B), white blood cell level ( Figure 5 C) and lymphocyte levels (as shown in Figure 5 In addition, the main organs of the mice, including the heart, liver, spleen, lung, kidney, rectum, and colon, were taken and histopathological sections were made. The results of the tissue sections showed that there was no obvious effect on the mouse tissues at this dosage (as shown in D). Figure 5 Based on the above results, the nanoparticles prepared by the present invention obviously have good biosafety.

[0078] To confirm the therapeutic effect of drug-loaded nanoparticles in vivo, this study used an orthotopic colorectal cancer mouse model to evaluate the antitumor effect and safety of 9Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid+5-FU. Different drugs were selected for oral or intraperitoneal administration (5-FU), and the drugs were administered every other day (e.g. Figure 6 The state of the colorectal cancer model was observed by fluorescence imaging counting on day 0 and day 14, and the tumor weight was recorded and calculated (as shown in Figure 2A). Figure 6 B) and body weight (as shown in Figure 6 Colorectal and tumor tissues were stained with HE.

[0079] The applicant further studied the in vivo therapeutic effect of drug-loaded nanoparticles from the perspective of inhibiting orthotopic colorectal cancer mouse tumors. Starting from the 5th day after CT26 cancer cell implantation, mice were orally administered β-acid, Fe3O4 / CS / TPP / β-acid, 9Fe3O4 / CS / TPP / β-acid, and 9Fe3O4 / CS / TPP / β-acid+5-FU every other day for 7 consecutive times ( Figure 6 A). The nanoparticles were manipulated using a magnet after each oral administration. Tumor-bearing mice were sacrificed on day 14 and the tumor size was assessed from the harvested colon. Figure 6 As shown in E, except for the vehicle group, the tumor size of other experimental groups showed a downward trend compared with the control group. In addition, among the different experimental groups, the colorectal cancer tumor weight in the drug-loaded nanoparticle group (9Fe3O4 / CS / TPP / β-acid) was lower than that in the 5-FU and β-acid groups. When 5-FU was used in combination with drug-loaded nanoparticles (9Fe3O4 / CS / TPP / β-acid+5-FU), the tumor weight decreased further, suggesting that 5-FU may have a synergistic effect with nanoparticles. In the evaluation of body weight changes, the body weight in the in situ colorectal cancer model showed a trend of first increasing and then decreasing on day 14, and there was no significant difference between the groups ( Figure 6 C). Combining the safety experiment with the anti-tumor experiment, it was shown that there was no obvious systemic toxicity by oral administration. From the fluorescence imaging results ( Figure 6D), it can be found that after the control group and the vector group were inoculated with CT26 cells, the fluorescence intensity in the mice showed an upward trend as the experimental time increased. The fluorescence intensity in the mice of the different drug-dosing groups (5-FU, β-acids, 9Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid+5-FU) showed a downward trend, which shows that the drug has an inhibitory effect on tumors. In addition, the experiment found that after receiving treatment with 9Fe3O4 / CS / TPP / β-acid and 9Fe3O4 / CS / TPP / β-acid+5-FU, the tumor fluorescence intensity of the two groups was significantly weakened compared with other groups. After the mice were dissected, Figure 6 E is a photo of the tumor-bearing colon after treatment. Compared with the control group and the Fe3O4 / CS / TPP / β-acid group, the tumor volume and number in the other drug-treated groups were reduced, which undoubtedly shows that the drug-loaded nanoparticles have an outstanding ability to inhibit tumor growth. H&E staining of tumor tissue ( Figure 6 F) shows that the tissue sections of the control group, 5-FU, β-acid and Fe3O4 / CS / TPP / β-acid treated cells showed typical tumor characteristics, with tumor invasion of the colon wall and destruction of the colon mucosal structure. Figure 6 In F, the tumor area is indicated by a blue asterisk, and tumor invasion of the colon mucosa is indicated by a green arrow. In contrast, after 9Fe3O4 / CS / TPP / β-acid treatment, tissue sections showed limited tumor area and well-preserved mucosal structure at the tumor invasion front, indicating a significant therapeutic effect. When 5-FU and 9Fe3O4 / CS / TPP / β-acid were used in combination, H&E staining showed that the mucosal structure on the invasion side was intact and the tumor area almost disappeared.

[0080] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.

Claims

1. A method for preparing pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid, characterized in that: The following steps are involved: (1) adding chitosan to an acetic acid solution, stirring and dissolving, and preparing a chitosan aqueous solution; (2) mixing the β-acid ethanol solution with the chitosan aqueous solution prepared in step (1) to obtain a mixed solution 1; (3) adding Fe3O4 to the mixed solution 1 prepared in step (2), and stirring to obtain a mixed solution 2; (4) Mixing the sodium tripolyphosphate solution with the mixed solution 2 prepared in step (3), and centrifuging to obtain the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid.

2. The method for preparing pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid according to claim 1, characterized in that: In step (1), the concentration of the acetic acid solution is 1-2%, and the concentration of chitosan in the chitosan aqueous solution is 1-20 mg / mL.

3. The method for preparing pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid according to claim 1, characterized in that: In step (2), the β-acid ethanol solution is a solution with a concentration of 1-50 mg / mL prepared by dissolving β-acid in anhydrous ethanol, the mixing ratio of the β-acid ethanol solution to the chitosan aqueous solution is 1:1-1:5, and the stirring is stirring at room temperature for 10-90 min.

4. The method for preparing pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid according to claim 1, characterized in that: In step (3), the amount of Fe3O4 added is 200-600 mg, and the stirring is carried out at room temperature for 1-2 hours.

5. The method for preparing pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid according to claim 1, characterized in that: In step (4), the concentration of the sodium tripolyphosphate solution is 1-10 mg / mL, the mass ratio of the mixed solution 2 to the sodium tripolyphosphate solution is 2:1, and the stirring is carried out at room temperature for 1-2 hours.

6. A pH-responsive magnetic Fe3O4-modified chitosan nanoparticle loaded with β-acid prepared by the preparation method according to any one of claims 1 to 5.

7. Use of the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid as claimed in claim 6 in the preparation of antibacterial drugs, characterized in that: The antibacterial activity includes inhibiting Escherichia coli and Staphylococcus aureus.

8. Use of the pH-responsive magnetic Fe3O4-modified chitosan nanoparticles loaded with β-acid as claimed in claim 6 in the preparation of anticancer drugs.

9. The use according to claim 8, characterized in that The anti-cancer effect is anti-colorectal cancer.

10. The use according to claim 9, characterized in that The colorectal cancer is colorectal cancer cell HCT-116.

Citation Information

Patent Citations

  • Beta-acid-loaded chitosan nano material as well as preparation method and application thereof

    CN116807996A